Asthma, Bronchiectasis, COPD, Respiratory Aspergillosis, Respiratory Candidiasis
Conditions
Brief summary
This study tests the effects of an experimental drug PC945 in people with asthma or other chronic respiratory diseases whose lungs are infected by Aspergillus fungi and Candida yeasts. PC945 may be useful in treating patients infected with Aspergillus as, unlike the usual treatments, it is inhaled into the lung and has been designed to stay there and treat the infection. Participants will continue to receive their usual treatment for their chronic respiratory disease. Half of the participants will receive PC945 and half will receive a placebo. The amount of fungus and yeast in the patients' phlegm will be measured over the course of the study. The study will take place at multiple sites in UK and will include approximately 46 participants. The maximum study duration will be about 16 weeks.
Interventions
DRUGPC945
Study drug under investigation
DRUGPlacebo
Placebo control
Sponsors
Pulmocide Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
This is a double-blind study.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Subject must be male or female, aged 18 years (inclusive) or older (at the time of consent). 2. Each subject must sign an informed consent form (ICF) indicating that he or she understands the purpose and requirements of the study and is willing to participate. 3. Subject's diagnosis of moderate to severe asthma (GINA Step 3 or 4) made by a respiratory physician and treated with an inhaled steroid or other chronic respiratory disease. 1. For subjects with asthma, the diagnosis of asthma must be supported either by: * i. Historical evidence of: * 1\. Increased airway hyper-responsiveness (methacholine PC20 \<8 mg/ml). * or * 2\. Airflow obstruction (FEV1/FVC ratio of less than 70%) and short-term variations in FEV1 (\>12%). * or * ii. Bronchodilator reversibility ≥12% or ≥200 mL improvement in FEV1 post bronchodilator after administration of a short-acting beta agonist at screening. OR 2. Subjects with other chronic respiratory disease (such as COPD or bronchiectasis) susceptible to fungal bronchitis. 4. Subject must have a positive sputum fungal culture with one or more colonies of A. fumigatus complex / A. niger complex or 200 or more colonies of yeast measured using a modified standard approach on one occasion obtained within the 28-day screening period. 5. Subject must be able to produce a spontaneous sputum sample.
Exclusion criteria
1. Subjects who have received more than 2 weeks of intravenous (IV), oral or inhaled antifungal therapy within 6 months prior to Visit 3 or any antifungal therapy (IV, oral or inhaled) within 2 months of Visit 3. 2. Subjects taking medication that could significantly increase the risks of AEs with triazoles. 3. Subjects who are receiving antiretroviral protease inhibitors. 4. Clinical or laboratory evidence of bacterial bronchitis at the point of screening. 5. Subjects who have used an experimental medical device or received an experimental drug within 3 months or within a period less than five times the experimental drug's half-life, whichever is longer, before the first dose of the study drug is scheduled. 6. Clinically significant screening abnormalities (including, but not limited to, vital signs, ECG, laboratory tests, physical examination and spirometry) that, in the Investigator's opinion, exclude the subject from participation in the study. 7. Positive test at screening for hepatitis B virus infection, or antibodies to hepatitis C virus. 8. If female, the subject is pregnant (e.g. has a positive serum β human chorionic gonadotropin at screening or a positive urinary pregnancy test pre-dose on Day 1), lactating or breast feeding. 9. Subject is an employee or a first-degree relative of anyone employed by Pulmocide, a participating clinical trial site, or any contract research organisation involved in the study. 10. Any other reason that the Investigator considers makes the subject unsuitable to participate.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Presence or absence of Aspergillus fumigatus (A. fumigatus) complex / Aspergillus niger (A. niger) complex colonies on sputum culture | Baseline to Day 32-35 | This is a binary endpoint |
| Reduction in the numbed of colonies of Candida species (spp) on sputum culture | Baseline to Day 32-35 | Substantial reduction in colony forming unit (CFU) count by at least 50% |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The number of sputum A. fumigatus complex / A. niger complex CFUs in fungal culture | Baseline to Day 84 | — |
| Sputum A. fumigatus measured by quantitative polymerase chain reaction (qPCR) | Baseline to Day 84 | — |
| Spontaneous sputum weight (24-hour collection) | Baseline to Day 84 | — |
| The number of sputum Candida spp. CFUs in fungal culture | Baseline to Day 84 | — |
| C. albicans measured by qPCR in sputum | Baseline to Day 84 | — |
| The concentration of A. fumigatus-specific immunoglobulin G (IgG) as measured in serum | Baseline to Day 84 | — |
| Serum Total immunoglobulin E (IgE) levels | Baseline to Day 84 | — |
| A. fumigatus-specific IgE levels | Baseline to Day 84 | — |
| Change in Asthma control questionnaire - 6 item [ACQ6] (Total score) in asthma patients only | Baseline to Day 84 | — |
| Change in Asthma Quality of Life Questionnaire - Juniper [AQLQ-J] (Total score) in asthma patients only | Baseline to Day 84 | — |
| Change in St George's Respiratory Questionnaire [SGRQ] (Total score) | Baseline to Day 84 | — |
| Change in Leicester Cough Questionnaire (Total score) | Baseline to Day 84 | — |
| Breathlessness visual analogue scale rating, change over time | Baseline to Day 84 | Symptom severity rated from Best ever to Worst possible |
| Predicted post bronchodilator forced expiratory volume in 1 second (FEV1) values | Baseline to Day 84 | — |
| Correlation between Candida albicans measured by qPCR and clinical response | Baseline to Day 84 | — |
| Area undertake curve from time 0 to 2h post dose (AUC(0-2)) | Baseline to Day 84 | Derived pharmacokinetic parameters for PC945 and the potential circulating metabolite(s), if detectable |
| Last quantifiable plasma concentration (Ct) | Baseline to Day 84 | Derived pharmacokinetic parameters for PC945 and the potential circulating metabolite(s), if detectable |
| maximum observed concentration (Cmax) | Baseline to Day 84 | Derived pharmacokinetic parameters for PC945 and the potential circulating metabolite(s), if detectable |
| concentration at the end of the dosage interval (Ctrough) | Baseline to Day 84 | Derived pharmacokinetic parameters for PC945 and the potential circulating metabolite(s), if detectable |
| Adverse events (AEs) incidence (safety and tolerability) | Baseline to Day 84 | — |
| Twelve-lead electrocardiogram (ECG) (Safety parameter) | Baseline to Day 84 | including QT interval corrected for Bazetts formula, QT interval, QRS Interval, PR Interval and ventricular rate). |
| Proportion of participants who meet the markedly abnormal criteria for vital signs assessment at lease once post dose | Baseline to Day 84 | — |
| Proportion of participants who meet the markedly abnormal criteria for safety laboratory assessment at lease once post dose | Baseline to Day 84 | — |
| Change in peak expiratory flow rate [PEFR] | Baseline to Day 84 | — |
| Antibiotic use | Baseline to Day 84 | — |
| Sputum characteristics - consistency and presence of blood (fresh morning sputum samples) | Baseline to Day 84 | — |
| Sputum colour (fresh morning sputum samples) | Baseline to Day 84 | — |
| Correlation between A. fumigatus measured by qPCR and clinical response | Baseline to Day 84 | — |
| Forced vital capacity (FVC) values | Baseline to Day 84 | — |
Countries
United Kingdom
Outcome results
None listed